Patents by Inventor Georges Muller

Georges Muller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060205787
    Abstract: This invention relates to racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof. Synthesis, methods of use, and pharmaceutical compositions of racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxo-piperidine-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof, are disclosed.
    Type: Application
    Filed: January 25, 2006
    Publication date: September 14, 2006
    Inventors: George Muller, Roger Chen
  • Publication number: 20060199819
    Abstract: The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are known to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Methods of using the compounds to inhibit prostaglandin synthesis are claimed.
    Type: Application
    Filed: May 4, 2006
    Publication date: September 7, 2006
    Inventors: Andrew Dannenberg, George Muller
  • Publication number: 20060183787
    Abstract: Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.
    Type: Application
    Filed: March 28, 2006
    Publication date: August 17, 2006
    Inventors: George Muller, Peter Schafer, Patricia Rohane
  • Publication number: 20060183910
    Abstract: Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNF? in a mammal.
    Type: Application
    Filed: April 12, 2006
    Publication date: August 17, 2006
    Inventors: George Muller, David Stirling, Roger Chen
  • Publication number: 20060183788
    Abstract: Methods of treating, managing or preventing exercise-induced asthma are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.
    Type: Application
    Filed: March 28, 2006
    Publication date: August 17, 2006
    Inventors: George Muller, Peter Schafer, Patricia Rohane
  • Publication number: 20060178402
    Abstract: Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNF? in a mammal.
    Type: Application
    Filed: April 12, 2006
    Publication date: August 10, 2006
    Inventors: George Muller, David Stirling, Roger Chen
  • Publication number: 20060160854
    Abstract: Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNF? in a mammal.
    Type: Application
    Filed: November 17, 2005
    Publication date: July 20, 2006
    Inventors: George Muller, David Stirling, Roger Chen
  • Publication number: 20060084815
    Abstract: The invention encompasses isoindoline compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.
    Type: Application
    Filed: July 28, 2004
    Publication date: April 20, 2006
    Inventors: George Muller, Hon-Wah Man
  • Publication number: 20060069126
    Abstract: Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group, which may be further substituted in the 5-position with alkyl or halogeno, and in the 4-position with alkyl or a nitrogen-containing group are inhibitors of, and thus useful in the treatment of disease states mediated by, TNF?. A typical embodiment is 2-(2,6-dioxo-3-hydroxy-5-fluoro-piperidin-5-yl)4-aminoisoindolin-1-one.
    Type: Application
    Filed: November 4, 2005
    Publication date: March 30, 2006
    Inventors: George Muller, Hon-Wah Man, David Stirling
  • Publication number: 20060058362
    Abstract: The invention encompasses 7-amido-isoindolyl compounds and methods of using these compounds and compositions in mammals for treatment, prevention or management of various diseases and disorders. Examples inlcude, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.
    Type: Application
    Filed: October 17, 2005
    Publication date: March 16, 2006
    Inventors: Hon-Wah Man, George Muller, Weihong Zhang
  • Publication number: 20060052609
    Abstract: The present invention concerns new processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines which are useful for preventing or treating diseases or conditions related to an abnormally high level or activity of TNF?. The invention provides processes for the commercial production of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines including, but not limited to, the therapeutically active 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione.
    Type: Application
    Filed: September 1, 2005
    Publication date: March 9, 2006
    Inventors: George Muller, Roger Chen, Manohar Saindane, Chuansheng Ge
  • Publication number: 20060052596
    Abstract: The present invention relates to substituted heterocyclic compounds and compositions comprising a substituted heterocyclic compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more substituted heterocyclic compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more substituted heterocyclic compounds. The present invention further relates to articles of manufacture and kits comprising one or more substituted heterocyclic compounds.
    Type: Application
    Filed: September 1, 2005
    Publication date: March 9, 2006
    Inventors: George Muller, Hon-Wah Man
  • Patent number: 7005438
    Abstract: Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group, which may be further substituted in the 5-position with alkyl or halogeno, and in the 4-position with alkyl or a nitrogen-containing group are inhibitors of, and thus useful in the treatment of disease states mediated by, TNF?. A typical embodiment is 2-(2,6-dioxo-3-hydroxy-5-fluoropiperidin-5-yl)-4-aminoisoindolin-1-one.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: February 28, 2006
    Assignee: Celgene Corporation
    Inventors: George Muller, Hon-Wah Man, David I. Stirling
  • Publication number: 20060030592
    Abstract: 1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines substituted in the 4- and/or 7-position of the isoindoline ring and optionally further substituted in the 3-position of the 2,6-dioxopiperidine ring reduce the levels of inflammatory cytokines such as TNF? in a mammal.
    Type: Application
    Filed: September 28, 2005
    Publication date: February 9, 2006
    Inventors: Hon-Wah Man, George Muller
  • Publication number: 20060025597
    Abstract: The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-? in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.
    Type: Application
    Filed: September 21, 2005
    Publication date: February 2, 2006
    Inventors: Michael Robarge, Roger Chen, George Muller, Hon-Wah Man
  • Publication number: 20060025457
    Abstract: Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.
    Type: Application
    Filed: July 28, 2004
    Publication date: February 2, 2006
    Inventors: George Muller, Hon-Wah Man
  • Publication number: 20060003979
    Abstract: Novel amides and imides are inhibitors of tumor necrosis factors and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions.
    Type: Application
    Filed: August 25, 2005
    Publication date: January 5, 2006
    Inventors: George Muller, Mary Shire
  • Publication number: 20050267196
    Abstract: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (?) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-? or the inhibition of PDE4.
    Type: Application
    Filed: June 28, 2005
    Publication date: December 1, 2005
    Inventors: George Muller, Peter Schafer, Hon-Wah Man, Chuansheng Ge
  • Publication number: 20050203090
    Abstract: The invention encompasses novel N-alkyl-hydroxamic acid-isoindolyl compounds, pharmaceutical compositions of these compounds, and methods of using these compounds and compositions for treatment or prevention of various diseases and disorders, for example, diseases associated with PDE4.
    Type: Application
    Filed: May 9, 2005
    Publication date: September 15, 2005
    Inventors: Hon-Wah Man, George Muller
  • Publication number: 20050192336
    Abstract: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (?) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-? or the inhibition of PDE4.
    Type: Application
    Filed: April 13, 2005
    Publication date: September 1, 2005
    Inventors: George Muller, Peter Schafer, Hon-Wah Man, Chuansheng Ge